Moderna, Inc. $MRNA Shares Newly Bought by Alta Advisers Ltd

Alta Advisers Ltd bought a new stake in Moderna, Inc. (NASDAQ:MRNA) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm bought 2,755 shares of the company’s stock, valued at approximately $531,000.

A number of other hedge funds have also recently made changes to their positions in MRNA. Merck & Co. Inc. acquired a new position in Moderna in the 2nd quarter valued at about $161,642,545. Bank of New York Mellon Corp acquired a new position in Moderna during the 2nd quarter worth about $119,168,000. Contravisory Investment Management Inc. raised its holdings in Moderna by 1,387.6% during the 2nd quarter. Contravisory Investment Management Inc. now owns 24,218 shares of the company’s stock worth $1,696,000 after buying an additional 22,590 shares during the period. TD Waterhouse Canada Inc. lifted its stake in shares of Moderna by 2,042.6% during the 3rd quarter. TD Waterhouse Canada Inc. now owns 72,591 shares of the company’s stock worth $13,722,000 after buying an additional 69,203 shares during the last quarter. Finally, Northwestern Mutual Wealth Management Co. acquired a new stake in Moderna in the second quarter valued at approximately $1,013,000. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Trending Headlines about Moderna

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Moderna reported third-quarter revenue of $1.31 billion, up 29.2% year over year, and earnings of $0.38 per share, far ahead of analysts’ expectations for a loss. Stronger overseas COVID-19 vaccine sales helped drive the results. Reuters report on revenue and demand
• Positive Sentiment: Management raised its 2026 revenue-growth forecast to 15%–25%, from a prior outlook of up to 10%. The company also said it plans to reduce research and development spending, supporting its near-term financial performance. CNBC outlook report
• Positive Sentiment: Health Canada authorized Moderna’s seasonal flu and flu-COVID combination vaccines for adults 50 and older, opening a potential new market for its mRNA products. CBC report on Canadian approvals
• Positive Sentiment: Investors are also watching prospects for Moderna’s cancer vaccine: CEO Stéphane Bancel said it could have potential beyond melanoma. That adds pipeline excitement, though future commercial value remains uncertain. Yahoo Finance report on cancer vaccine prospects
• Neutral Sentiment: Moderna and GSK settled a patent dispute involving Moderna’s COVID and RSV shots. The settlement removes a source of legal uncertainty, but the available report does not specify its financial terms. Reuters report on patent settlement
• Negative Sentiment: The sharp rally has heightened concerns that expectations for the cancer-vaccine pipeline may be running ahead of near-term revenue potential. Moderna’s longer-term prospects still depend on sustaining vaccine sales and turning pipeline advances into commercial products. Barron’s analysis of Moderna’s earnings and valuation

Moderna Trading Up 5.3%

Shares of NASDAQ:MRNA opened at $254.19 on Friday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 2.18 and a current ratio of 2.29. The firm has a fifty day moving average price of $191.85 and a 200 day moving average price of $91.51. Moderna, Inc. has a fifty-two week low of $22.28 and a fifty-two week high of $267.50.

Moderna (NASDAQ:MRNA) last released its quarterly earnings data on Friday, November 6th. The company reported $0.38 earnings per share for the quarter, beating analysts’ consensus estimates of ($1.10) by $1.48. The business had revenue of $1.31 billion during the quarter, compared to analyst estimates of $890.25 million. Moderna had a negative return on equity of 28.30% and a negative net margin of 141.43%. The company’s revenue was up 29.2% on a year-over-year basis. During the same quarter last year, the business posted ($0.51) EPS. On average, equities analysts forecast that Moderna, Inc. will post -6.11 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the company. Bradesco Corretora raised Moderna to an “outperform” rating in a research note on Friday, August 28th. Brookline Capital Markets reaffirmed a “buy” rating on shares of Moderna in a research note on Wednesday, August 19th. Wolfe Research raised shares of Moderna from an “underperform” rating to a “peer perform” rating in a report on Tuesday, August 25th. Berenberg Bank boosted their target price on shares of Moderna from $45.00 to $100.00 and gave the company a “hold” rating in a research note on Friday, September 11th. Finally, Singular Research raised Moderna to a “hold” rating in a research report on Wednesday, September 23rd. Six investment analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and four have issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $107.10.

Insider Activity at Moderna

In related news, CFO James M. Mock sold 34,836 shares of Moderna stock in a transaction dated Thursday, September 10th. The stock was sold at an average price of $134.49, for a total value of $4,685,093.64. Following the completion of the transaction, the chief financial officer owned 59,375 shares in the company, valued at approximately $7,985,343.75. This trade represents a 36.98% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Shannon Klinger sold 3,471 shares of the company’s stock in a transaction on Tuesday, September 1st. The stock was sold at an average price of $139.95, for a total transaction of $485,766.45. Following the transaction, the insider owned 74,129 shares of the company’s stock, valued at $10,374,353.55. This represents a 4.47% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 197,251 shares of company stock worth $33,875,904 in the last ninety days. Company insiders own 10.80% of the company’s stock.

About Moderna

Moderna, Inc is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can help prevent or treat disease.

The company’s commercial products include Spikevax, a vaccine against COVID-19, and mRESVIA, a vaccine against respiratory syncytial virus (RSV). Moderna also researches potential mRNA-based vaccines and treatments for infectious diseases, cancer, and rare diseases.

Founded in 2010 as Moderna Therapeutics, the company is headquartered in Cambridge, Massachusetts.